MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Clinical trials for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets fatty liver in transplant patients
Disease control Recruiting nowThis study tests whether resmetirom, a daily pill, can reduce liver fat in people who have had a liver transplant and developed MASH (a type of fatty liver disease). About 120 participants will be randomly assigned to receive either resmetirom or a placebo for 28 weeks. The main …
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to halt liver scarring in 2,150 patients with fatty liver disease
Disease control Recruiting nowThis phase 3 trial tests efruxifermin, a weekly injection, in 2,150 adults with liver scarring (cirrhosis) caused by NASH/MASH, a type of fatty liver disease. Half get the drug, half get a placebo. The goal is to see if efruxifermin can prevent serious liver events like liver fai…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug cocktail aims to reverse fatty liver damage in diabetics
Disease control Recruiting nowThis study tests whether a drug called chiglitazar, combined with anti-inflammatory and liver-protecting therapies, can improve liver health in people who have both MASH (a severe fatty liver disease) and type 2 diabetes. About 300 adults will receive either the drug combo or a p…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Old heart drug could be new hope against fatty liver
Disease control Recruiting nowThis study tests whether a low dose of digoxin, a drug normally used for heart problems, can help people with a severe type of fatty liver disease called NASH (also known as MASH). The trial will involve 144 adults with biopsy-confirmed NASH and liver scarring. Participants will …
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New shot for fatty liver disease enters human testing
Disease control Recruiting nowThis study tests an investigational drug called TGM-312-SC01, given as a shot, for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition. It first checks safety and drug levels in healthy adults, then in people with MASH. The trial is currently recrui…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE1, PHASE2 • Sponsor: Tangram Therapeutics Plc • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug HU6 targets fatty liver disease in Mid-Stage trial
Disease control Recruiting nowThis study tests a new drug called HU6 for people with MASH, a serious fatty liver disease. About 180 adults aged 30 and older will receive either HU6 or a placebo to see if the drug safely reduces liver fat. The trial lasts 26 weeks and focuses on safety and how well the drug wo…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Rivus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
FDA-Approved MASH drug gets Real-World test in pakistan
Disease control Recruiting nowThis study tests resmiterom, the first FDA-approved drug for MASH (a type of fatty liver disease), in 165 Pakistani patients. Researchers will check how safe it is and whether it improves liver health using non-invasive scans. The goal is to see if the drug works well in this spe…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE4 • Sponsor: Nabiqasim Industries (Pvt) Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a quick liver scan replace needle biopsies for MASH in diabetics?
Diagnosis Recruiting nowThis study is testing a new, non-invasive liver scan called iLivTouch to see if it can accurately detect a serious liver condition called MASH in people who have both type 2 diabetes and fatty liver disease. The scan measures liver inflammation, fat, and stiffness without any nee…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
Can eating only during an 8-10 hour window help liver cancer patients?
Symptom relief Recruiting nowThis study is testing whether a time-restricted eating plan (eating only during an 8-10 hour window each day) combined with a healthy plant-based diet is safe and doable for people with liver cancer, cirrhosis, or fatty liver disease. Fifty overweight or obese adults will either …
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: NA • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
New registry tracks rezdiffra safety for moms and babies
Knowledge-focused Recruiting nowThis study tracks the safety of the liver drug Rezdiffra (resmetirom) in women with NASH who take it while pregnant or breastfeeding. Researchers will follow about 10 women and their infants up to 12 months old to check for birth defects, growth problems, and other health issues.…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Fatty liver linked to colon polyp genes? new study investigates
Knowledge-focused Recruiting nowThis study looks at the genes in colon polyps from people with MASH (a type of fatty liver disease) compared to those without fatty liver. Researchers want to find specific gene patterns that might signal higher risk. About 100 adults already scheduled for polyp removal will dona…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Sponsor: Shanghai East Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC